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Olanzapine: A potent agonist at the hM4D(Gi) DREADD 
amenable to clinical translation of chemogenetics
Mikail Weston1*, Teresa Kaserer2*, Angela Wu3, Alexandre Mouravlev3, Jenna C. Carpenter1, 
Albert Snowball1, Samuel Knauss1†, Melanie von Schimmelmann4, Matthew J. During4, 
Gabriele Lignani1, Stephanie Schorge1‡, Deborah Young3, Dimitri M. Kullmann1§, Andreas Lieb1§
Designer receptors exclusively activated by designer drugs (DREADDs) derived from muscarinic receptors not only 
are a powerful tool to test causality in basic neuroscience but also are potentially amenable to clinical translation. 
A major obstacle, however, is that the widely used agonist clozapine N-oxide undergoes conversion to clozapine, 
which penetrates the blood-brain barrier but has an unfavorable side effect profile. Perlapine has been reported 
to activate DREADDs at nanomolar concentrations but is not approved for use in humans by the Food and Drug 
Administration or the European Medicines Agency, limiting its translational potential. Here, we report that the 
atypical antipsychotic drug olanzapine, widely available in various formulations, is a potent agonist of the human 
M4 muscarinic receptor-based DREADD, facilitating clinical translation of chemogenetics to treat central nervous 
system diseases.
INTRODUCTION
Central nervous system (CNS) diseases caused by abnormal circuit 
function represent a major burden to society. Although many respond 
to conventional small-molecule treatment, some diseases such as 
intractable pain and refractory epilepsy account for a substantial 
unmet need. Drug-resistant focal epilepsy alone affects approxi-
mately 0.2% of the entire population (1, 2). Although surgical resection 
of the epileptogenic zone is effective, it is contraindicated in the 
overwhelming majority of patients because of high risks of perma-
nent disability associated with brain tissue removal (3). Several gene 
therapies for refractory epilepsy, based on altering the balance of 
excitation and inhibition, have been validated in preclinical models 
(4–9). Chemogenetics using viral vector–mediated expression of 
the inhibitory muscarinic M4 receptor–based Gi-coupled DREADD 
(designer receptor exclusively activated by designer drug) hM4D(Gi) 
is especially promising because the therapeutic effect can be titrated 
by adjusting the dose of the activating ligand (10). Several recent 
publications have shown that hM4D(Gi) expressed in epileptogenic 
zones can suppress partial-onset seizures when activated (5, 11, 12).
A potential limitation to clinical translation of DREADD tech-
nology is that most studies to date have used clozapine N-oxide 
(CNO), the inactive metabolite of the atypical antipsychotic drug 
clozapine (CZP) (13), as the ligand. CNO is not approved for clinical 
use, and recent evidence shows that CNO is actively exported from 
the CNS and back-converted to CZP, which crosses the blood-brain 
barrier and subsequently acts as the ligand activating the DREADD 
(14, 15). CZP as an activator of hM4D(Gi), however, represents major 
logistical and regulatory obstacles because it has an unfavorable side 
effect profile, including a risk of agranulocytosis and myocarditis, 
and can reduce seizure threshold (16–18). Related antipsychotic 
drugs have been proposed as potential agonists (13, 14), and two 
other drugs activating DREADDs have recently been described: 
“compound 21” (C21) and perlapine (PLP) (19, 20). Although PLP 
has previously been used as a mild sedative antihistamine drug in 
Japan, neither it nor C21 is approved for clinical use by the Food and 
Drug Administration (FDA) or the European Medicines Agency 
(EMA). Identification of an FDA/EMA-approved drug for repur-
posing as a DREADD activator would facilitate clinical translation of 
DREADD technology to treat CNS diseases.
RESULTS
hM4D(Gi)-dependent Kir3.1 and Kir3.2 activation
To measure Gi-coupled hM4D(Gi) activation, we established an 
electrophysiological screen based on measuring the potentiation of 
the inward-rectifying potassium current in a human embryonic 
kidney cell line stably expressing Kir3.1 and Kir3.2 (Fig. 1A) (21). 
We verified the sensitivity of the system by estimating the half-maximal 
effective concentration (EC50) of CZP as 61 ± 19 nM (mean ± SEM; 
Hill coefficient, 1.44 ± 0.28; n = 6), close to the reported EC50 of 
57 nM (13). We used CNO (1 M) as a positive control to define 
maximal activation of hM4D(Gi) (Fig. 1B) and confirmed that CZP, 
PLP, and C21 are efficacious agonists (maximal activation of 
inward-rectifying current in comparison to 1 M CNO: CZP/CNO = 
1.14 ± 0.06, n = 6; PLP/CNO = 1.17 ± 0.16, n = 9; C21/CNO = 1.11 ± 
0.07). C21 showed a significantly lower EC50 than CZP [CZP EC50 = 
61 ± 19 nM; PLP EC50 = 40 ± 10 nM; Hill coefficient, 1.69 ± 0.39; 
C21 EC50 = 20 ± 4 nM; Hill coefficient, 1.36 ± 0.22; EC50 difference 
P < 0.05, one-way analysis of variance (ANOVA) with Bonferroni 
post hoc test]. Although C21 is a potent agonist of hM4D(Gi), addi-
tional pharmacokinetic and safety characterization would be required 
before clinical translation (19). We therefore performed a shape 
[three-dimensional (3D)] (22, 23) and 2D similarity screen (24) to 
identify FDA/EMA-approved drugs with structural and electro-
chemical properties similar to those of C21 (Fig. 2A). Prioritized 
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drugs with similarity indicated by the TanimotoCombo score for 
the 3D screen, and by similarity for the 2D-based screen, are listed 
in Fig. 2B and table S1.
hM4D(Gi) activation with drugs identified by similarity screens
We tested olanzapine (OZP; 3D rank 1), promazine (PZN; 3D rank 2), 
tripelennamine (TNA; 3D rank 5), diphenhydramine (DPH; 3D rank 6), 
chlorprothixen (CPX; 3D rank 9), and amoxapine (AXN; 2D rank 2). 
We also tested the first, putative active metabolite of quetiapine 
(2D rank 6), norquetiapine (NQN) (25) (for chemical structures of 
all tested molecules, see table S2). Of all the drugs tested, only OZP 
was able to fully activate hM4D(Gi) at a concentration between 100 
and 300 nM using 1 M CNO as control as above (OZP/CNO = 1.18 ± 
0.13; n = 3) (Fig. 2B). A full dose-response curve for OZP revealed 
an EC50 of 5 ± 2 nM (Hill coefficient, 1.11 ± 0.25; n = 6), significantly 
lower than that of CZP (EC50 = 61 ± 19 nM, n = 6; P = 0.0128, Stu-
dent’s t test) (Fig. 3A). To gain further insights into the observed 
activity differences on a molecular level, we docked OZP, CZP, and 
CPX into an active-state homology model of hM4D(Gi) using an 
induced fit procedure. In addition to the ionic interactions with 
D112, the docking poses of OZP suggest stacking interactions with 
W164 and hydrogen bonds involving Y116 and N117 (Fig. 3B). In 
addition, the OZP methyl group extends into a side pocket that is 
also occupied by the agonist iperoxo in the hM2 crystal structure 
complex [Protein Data Bank (PDB) entry 4MQS (26); fig. S1A]. 
This hydrophobic pocket is less occupied by CZP, which, in combi-
nation with lack of a hydrogen bond with the N117 amino group 
(Fig. 3B), could explain the lower activity of CZP compared to 
OZP. In contrast, the geometry of the inactive CPX and its lack of 
heteroatoms prevent the formation of any of the hydrogen bonds 






































































Fig. 1. Electrophysiology-based screen of hM4D(Gi) activation. (A) Left: Representative traces of Kir3.1 and Kir3.2 currents with (+CNO 1 M, bottom) and without (baseline, 
top) hM4D(Gi) agonist application. Middle: Mean current measured during the time indicated by the gray area in the left panel, plotted against holding voltage. The red line 
indicates the calculation of the membrane leak conductance, obtained from a linear fit between 0 and +50 mV. Right: Leak-subtracted Kir3.1/Kir3.2-mediated currents, 
together with a linear fit to currents at negative potentials (blue). The slope of the current-voltage relationship (k) was used for subsequent analysis of hM4D(Gi) activation. 
(B) Left: CZP, C21, and PLP act as potent agonists of hM4D(Gi). All data are shown normalized to CNO (1 M) as a positive control and fitted by a Hill equation. Right: EC50 of 






































































Fig. 2. Shape- and 2D similarity–based identification of hM4D(Gi) agonists. (A) Overview of the 3D- and 2D-based virtual screen. C21 was used as the query com-
pound for both the 2D similarity search of the ChEMBL database and the generation of a 3D shape–based model, because it showed the lowest EC50 at hM4D(Gi) of known 
agonists. For detailed virtual screening results, see table S1. (B) hM4D(Gi)-dependent potentiation of Kir3.1/Kir3.2-mediated currents measured for selected hit com-
pounds is normalized by 1 M CNO as positive control. The TanimotoCombo (TC) score (for 3D screen), similarity (S) index (for 2D screen), the screening method (3D or 
2D; separated by dotted line), and the tested concentration are indicated. For detailed structures of selected drugs, see table S2.
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In vivo verification that OZP activates hM4D(Gi)
To test whether OZP is effective in vivo, we redesigned a codon- 
optimized version of hM4D(Gi) linked via a viral self-cleaving 2A 
peptide to green fluorescent protein (GFP) [hM4D(Gi)opt] and put 
it under control of a human Ca2+/calmodulin-dependent protein kinase 
II (CamKII) promoter (hCamKII) for preferential expression in 
forebrain principal neurons (27). We verified that the EC50 of OZP 
at hM4D(Gi)opt (7 ± 2 nM; Hill coefficient, 1.20 ± 0.17; n = 6) was 
similar to the EC50 at the original hM4D(Gi) (5 ± 2 nM, n = 6) 
(Fig. 3A, right). Postnatal day 0 (P0) mice were randomized for injec-
tion of either 2.5 l of AAV (adeno-associated virus) 2/8-hCamKII- 
hM4D(Gi)opt or 2.5 l of AAV2/8-hCamKII-GFP (control) into both 
lateral ventricles (Fig. 3C, right). A third group of mice received 
no injection. After a period of training, their performance on the 
rotarod was then tested at ~P42, while blinded to the viral injec-
tion. All mice received an acclimatization session on the rotarod 
on the day of testing, followed by two test sessions, one before and 
one after ligand injection. We injected OZP at a dose of 0.1 mg/kg 
intraperitoneally (i.p.). This dose corresponds to a peak plasma 
concentration below that which is associated with weight gain in chronic 
treatment, one of the most commonly reported side effects of OZP 
therapy (28, 29). OZP significantly reduced the latency to fall from 
149 ± 14 s to 111 ± 11 s (n = 15; P = 0.002, Student’s paired t test) in 
AAV2/8-hCamKII-hM4D(Gi)opt–injected animals. OZP had no effect 
on AAV2/8-hCamKII-GFP–injected animals [control, 180 ± 21 s; 
OZP, 169 ± 25 s; n = 15; P = 0.568, Student’s paired t test; compar-
ison with AAV2/8-hCamKII-hM4D (Gi)opt, P = 0.045, repeated-measures 
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Fig. 3. OZP is a potent agonist at hM4D(Gi). (A) Left: Dose-response curves for CZP and OZP at hM4D(Gi). The inset shows the efficacy of OZP (100 nM) and CZP (1 M), 
normalized to 1 M CNO as a positive control (CZP/CNO = 1.14 ± 0.06; n = 6; OZP/CNO = 1.01 ± 0.06; n = 6; P = 0.12, Student’s t test). Right: EC50 for CZP at hM4D(Gi), and 
OZP at hM4D(Gi) and at the codon-optimized hM4D(Gi)opt [CZP: hM4D(Gi) EC50 = 61 ± 19 nM, n = 6; OZP: hM4D(Gi) EC50 = 5 ± 2 nM, n = 6, P < 0.01 in comparison to CZP 
hM4D(Gi); OZP: hM4D(Gi)opt EC50 = 7 ± 2 nM, n = 6, P < 0.01 in comparison to CZP hM4D(Gi); one-way ANOVA with Bonferroni post hoc test]. ns, not significant. (B) Dock-
ing poses of OZP (left, blue sticks) in comparison to CZP (right, rose sticks) in the homology model of active hM4D(Gi) (gray cartoon and sticks). Ionic interactions with 
D112 and hydrogen bonds are highlighted by dotted and dashed lines, respectively. The methyl group of OZP is highlighted in the right panel. The Y113C and A203G 
mutations are highlighted in orange, and residues 434 to 443 are not depicted for clarity. (C) Left: Latency to fall of animals injected with AAV2/8-hCamKII-hM4D(Gi)opt 
[before OZP: 149 ± 14 s; after OZP (0.1 mg/kg, i.p.): 111 ± 11 s; n = 15; **P = 0.002, paired Student’s t test], those injected with AAV2/8-hCamKII-GFP (before OZP: 180 ± 21 s; 
after OZP: 169 ± 25 s; n = 15), and sham-injected animals (before OZP: 212 ± 21 s; after OZP: 189 ± 20s; n = 6; **P < 0.01, Student’s paired t test; #P < 0.05, repeated-measures 
ANOVA with LSD post hoc test). Middle: Normalized latency to fall of AAV2/8-hCamKII-hM4D(Gi)opt–injected animals treated with either OZP (0.1 mg/kg) (0.76 ± 0.06; 
n = 15) or CZP (0.1 mg/kg) (1.03 ± 0.08; n = 15; **P = 0.033, Student’s paired t test). Right: Representative confocal fluorescence images of mouse brains injected with either 
AAV2/8-hCamKII-hM4D(Gi)opt (DREADD, −1.3 mm from bregma) or AAV2/8-hCamKII-GFP (GFP, −1.2 mm from bregma) (scale bars, 1 mm). (D) Latency to fall after OZP 
(0.1 mg/kg, i.p.) in animals injected with either AAV2/5-hCamKII-hM4D(Gi) or AAV2/5-hCamKII-empty bilaterally into striatum [AAV2/5-hCamKII-hM4D(Gi), 19 ± 4 s; 
n = 6; AAV2/5-hCamKII-empty, 44 ± 8 s; n = 6; P = 0.014, Student’s unpaired t test].
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viral injection [control, 212 ± 21 s; OZP, 189 ± 20s; n = 6; P = 0.109, 
Student’s paired t test; P = 0.028, repeated-measures ANOVA with 
least significant difference (LSD) post hoc test] (Fig. 3C, left). A similar 
dose of CZP (0.1 mg/kg) had no effect on the same AAV2/8-hCamKII- 
hM4D(Gi)opt–injected animals, where OZP was effective [control, 
150 ± 18 s; CZP (0.1 mg/kg), 143 ± 12 s; P = 0.593, Student’s paired 
t test]. Expressing the effect of hM4D(Gi) activation as a ratio of 
latency to fall with and without drug (latency+drug/latency–drug), AAV2/8-
hCamKII-hM4D (Gi)opt–injected animals were significantly more 
sensitive to OZP (0.76 ± 0.06; n = 15) than CZP (1.03 ± 0.08; n = 15; 
P = 0.003, Student’s paired t test) (Fig. 3C, middle). The failure of CZP 
(0.1 mg/kg) to alter motor behavior contrasts with a previous re-
port (15), consistent with a relatively low level of hM4D(Gi) ex-
pression in the present study.
Last, we removed the fluorescent tag from the original hM4D(Gi) 
and injected either AAV2/5-hCamKII-hM4D(Gi) or a control empty 
vector (AAV2/5-hCamKII-empty) bilaterally into the striatum of adult 
rats. After four training sessions to acclimatize animals, during 
which the two groups of rats performed equivalently, we tested 
the effect of OZP (0.1 mg/kg). The latency to fall in animals injected 
with AAV2/5-hCamKII-hM4D(Gi) (19 ± 4 s, n = 6) was signifi-
cantly shorter than that in animals injected with empty vector control 
(AAV2/5-hCamKII-empty) (44 ± 8 s, n = 6; P = 0.014, unpaired 
Student’s t test) (Fig. 3D).
DISCUSSION
Although recent papers highlight the potential of PLP or C21 as 
potent activators of hM4D(Gi) (19), these ligands would require 
extensive screening to be approved for clinical use (30). PLP was 
marketed in Japan but was subsequently withdrawn, calling for an 
alternative licensed drug that can be repurposed as an activator of 
hM4D(Gi) for clinical translation of DREADD technology. The 
present study shows that OZP (ranked first in the 3D-based in silico 
screen) is a potent activator of hM4D(Gi). OZP is a second- 
generation atypical antipsychotic, which is approved by the FDA 
and EMA for treatment of schizophrenia and manic episodes in 
bipolar disorder. Common side effects of OZP at doses used in 
schizophrenia and bipolar disorder include weight gain, postural 
hypotension, and sedation (31). OZP is a D2 receptor antagonist, 
and its side effect profile therefore also includes akathisia, tardive 
dyskinesia, and neuroleptic malignant syndrome, although these 
are much less common than for first- generation antipsychotic drugs 
such as haloperidol and chlorpromazine. The in vitro EC50 of OZP 
at hM4D(Gi) is in the range of affinities reported for its native drug 
targets (table S3) (32). The ability to affect performance on the rotarod 
with OZP (0.1 mg/kg) reported here is consistent with the princi-
ple of receptor reserve, whereby GPCR (heterotrimeric guanine 
nucleotide–binding protein– coupled receptor)–mediated effects can 
be achieved with low doses of agonist (33). Given that CZP is typ-
ically only prescribed for treatment- resistant patients because of its 
unfavorable side effect profile (34), CZP is much less suitable for 
repurposing as a DREADD activator. Nevertheless, the side effect pro-
file of each activator must be considered and determined individually 
for every potential clinical application of hM4D(Gi). We therefore pro-
pose that OZP, which is widely available in oral, intramuscular, and 
intravenous formulations, is suited for clinical translation of 




Kir3.1/3.2 stable expressing cell line (35) was cultured in Dulbecco’s 
modified Eagle’s medium GlutaMax (Gibco), supplemented with 
10% fetal bovine serum (Gibco) and penicillin/streptomycin (50 IU/ml; 
Gibco), and contained Geneticin (500 g/ml) (Gibco) as a selection 
marker. Cells were transiently transfected with TurboFect transfec-
tion reagent (Thermo Fisher Scientific) with 3 g of hM4D(Gi) plasmid 
(Addgene; 45548) and 1 g of cytomegalovirus promoter (CMV)–GFP 
for cell identification. Standard whole-cell patch-clamp experiments 
were performed after 2 to 3 days as previously described (27). Briefly, 
borosilicate-glass electrodes were pulled (Sutter Instrument) and 
fire-polished (Narishige) with a final resistance of 2 to 4.5 megohms. 
The extracellular recording solution contained 140 mM KCl, 2.6 mM 
CaCl2, 1.2 mM MgCl2, and 10 mM Hepes, adjusted to pH 7.4 
with KOH. The intracellular recording solution contained 107 mM 
KCl, 1.2 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, 5 mM Hepes, 
2 mM Mg-ATP, and 0.3 mM NA2-GTP, adjusted to pH 7.2 with 
KOH. Cells were voltage-clamped at a holding potential of 0 mV, 
and a 100-ms step depolarization from –100 to +50 mV was ap-
plied in 10-mV increments and a 30-s interpulse interval. Whole-cell 
currents were low-pass–filtered at 2 kHz (Axopatch-1D; Axon In-
struments) and digitized at 10 kHz. The membrane leak conduc-
tance in each cell was estimated from a linear fit to currents measured 
between 0 and +50 mV. The inward-rectifying conductance me-
diated by Kir3.1/3.2 was estimated from a linear fit to currents between 
−100 and 0 mV after subtracting the leak conductance (Fig. 1A). 
All recordings were performed at room temperature, and the different 
drugs were applied by a custom-built perfusion system. CNO (Generon; 
#HY17366), PLP (Tocris Bioscience; #5549), C21 (Hello Bio; #HB6124), 
CZP (Cayman Chemical; #12059), OZP (Santa Cruz Biotechnology; 
#sc-212469), PZN (Sigma-Aldrich; #46674), TNA (Santa Cruz 
Biotechnology; #sc-229608), DPH (Cerilliant; #D-015), CPX (Santa 
Cruz Biotechnology; #sc-211077), NQN (BioVision; #2362), and 
AXN (LKT Laboratories; #A5059) were dissolved in either dimethyl 
sulfoxide (DMSO) or extracellular recording solution at a stock 
concentration of 1 mM and subsequently diluted to specified con-
centrations. CNO (1 M) was routinely tested to estimate maximal 
activation of hM4D(Gi) in each cell, and the Kir3.1/3.2- mediated 
conductance activated by each agonist application was therefore 
related to that evoked by 1 M CNO.
Molecular biology
The hM4D(Gi) plasmid was purchased from Addgene (#45548). Stan-
dard molecular biology techniques were used to clone GFP-T2A into an 
AAV2 transfer plasmid (GeneOptimizer, GeneArt; Thermo Fisher Scien-
tific). The codon-optimized version of HA-hM4D (Gi) full sequence is 
available upon request) was linked to GFP via a viral 2A peptide, 
and contained a woodchuck hepatitis posttranscriptional regulatory 
element (WPRE). For all in vivo experiments, the CMV promoter 
was replaced with a 1.3 kb CamKII promoter to allow expression 
in excitatory neurons (27), the antibiotic resistance was changed from 
ampicillin to kanamycin, and a restriction site after the 2A peptide 
was removed. A stop codon and restriction site after the hM4D(Gi) 
reading frame was inserted using polymerase chain reaction methods 
to facilitate excision of a nontagged hM4D(Gi) from an hM4D(Gi) 
mCherry plasmid (Addgene; #50477). The untagged hM4D(Gi) frag-
ment was cloned into an AAV expression plasmid under the control of 
the human CamKII promoter and containing a WPRE and bovine 
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growth hormone polyA and flanked by AAV2-inverted terminal 
repeats. AAV8 or AAV5 serotype vectors were packaged using methods 
described previously (36).
In silico screening
One low-energy conformation of C21 calculated with Omega 2.3.2 
(37, 38) was used as the query for the generation of the shape-based 
model. The default model was modified, and the final model only 
contained the color features shown in Fig. 2A. A maximum number 
of 200 conformers were generated for DrugBank version 5.0.7 (39) 
with Omega 2.3.2 (37, 38). The default settings of vROCS 3.0.0 
(22, 23) were used for screening, and hits were ranked according to 
the TanimotoCombo score. The ChEMBL (24) web service (www.
ebi.ac.uk/chembl/; access date 21 June 2017) was used to find FDA/
EMA-approved drugs with similar 2D structure to C21.
Homology modeling and docking
The crystal structure of hM2 in the active state in complex with 
the agonist iperoxo [PDB entry 4MQS (26)] was used as a tem-
plate to create a homology model of active hM4 in MOE 2018.0101 
(40). The hM4 sequence used for homology modeling already 
contained the Y113C and A203G mutations. The default settings 
were applied, except that iperoxo was considered during model 
generation and refinement. Iperoxo from the hM2 crystal struc-
ture was copied into the hM4 model, and the complex was pre-
pared using the Protein Preparation Wizard (41, 42) in Maestro 
release 2017-2 (43). The ligands were docked into the hM4 model 
using induced fit docking in Maestro release 2017-2. Redocking 
was performed with XP settings; otherwise, the default parameters 
were applied. Figures of the structures and docking poses were 
created with PyMOL (44).
Viral injections
All animal procedures were performed in accordance with the University 
College London and the University of Auckland  animal care committee’s 
regulations. Viral aliquots of AAV2/8-CamKII-GFP-T2A-hM4D(Gi)opt 
or AAV2/8-CamKII-GFP (both titers, >1011 GC/ml; VectorBuilder) 
were prepared and coded by a researcher conducting neither surgical 
procedures nor behavioral analyses. P0 neonatal CL57BL/6 mice were 
anesthetized with intraperitoneal ketamine (6 mg/kg) and midazolam 
(0.2 mg/kg). A 10-l microinjection syringe fitted with a 32-gauge 
angled needle (Hamilton) was filled with one virus. Mouse pups (n = 30) 
were divided equally between viral types and manually injected with 
2.5 l into each lateral ventricle, approximately 1 mm lateral from the 
sagittal suture and halfway between lambda and bregma, to optimize 
widespread cerebral transduction. Six pups received no injection. 
Pups’ paws were marked with green tattoo ink to allow differentia-
tion between viral types, and after recovery, they were returned to 
their home cage. Male adult Sprague-Dawley rats (150 to 200 g) re-
ceived a 3-l injection (200 nl/min) of AAV2/5-hCAMKII- hM4D(Gi) 
(4.36 × 1012 GC) or AAV2/5-hCamKII empty vector (4.14 × 1012 GC) 
bilaterally into the striatum (coordinates from bregma: anterior-posterior, 
1.0 mm; medial-lateral, ±2.6 mm; dorsal-ventral, –5.5 mm), with a 33-gauge 
Neuros syringe (Hamilton).
Behavioral analysis
At P35, mice were trained on a mouse rotarod (Ugo Basile). Mice were 
initially acclimatized for 10 min on the rotarod turning at 5 rpm, 
replacing them each time they fell off, followed by acceleration over 
a 5-min period from 5 to 40 rpm. The sequence was repeated four 
times. The latency to fall or to three consecutive cartwheels was re-
corded. Training was repeated daily until every mouse’s performance 
reached a plateau, taking approximately 2 weeks.
On the day of DREADD agonist testing, the mice had a further 
acclimatization session (5 min at 5 rpm, followed by four accelera-
tions), followed by a break of at least 30 min. They were then tested 
twice, with the same protocol as the acclimatization session, before, 
and 20 min after intraperitoneal injection of OZP (0.1 mg/kg). OZP 
and CZP were dissolved in 0.5% DMSO/0.9% NaCl to a concentra-
tion of 0.01 mg/kg before injection. The latency to falling off or cart-
wheeling was recorded.
To test rotarod performance in rats, animals were initially trained 
4 weeks after virus injection, on four consecutive days at a fixed 
rotation speed of 10 rpm (three trials on each day), and allowed to 
remain on the rotarod for up to 300 s. All six control rats and five 
of six rats in the AAV2/5-hCamKII-hM4D(Gi) group learned to 
remain on the rotarod for 300 s in the final training session. On 
day 5, rats were administered OZP (0.1 mg/kg, i.p.) and tested on 
an accelerating rotarod 10 min later (with a start speed of 4 rpm, 
reaching a final speed of 20 rpm after 30 s). Behavioral tests were 
performed by a researcher blinded to viral treatment.
Confocal fluorescence
To establish the extent of viral transduction, mice were anesthe-
tized with pentobarbital (150 mg/kg) (Boehringer Ingelheim) and 
transcardially perfused with 20 ml of heparinized (80 mg/liter) 
phosphate-buffered saline (Sigma-Aldrich) until the perfusate was 
clear and then with 4% paraformaldehyde (PFA; Tocris Bioscience) 
(20 ml). Brains were extracted and immersed in 4% PFA for a further 
24 hours before coronal vibratome slicing (Leica VT1000 S) at 50 m, 
mounting on slides with VECTASHIELD mounting medium with 
4′,6-diamidino-2-phenylindole (Vector Labs), and confocal fluores-
cence imaging (Zeiss LSM 710) to visualize GFP expression.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5.01 or IBM 
SPSS 22.0.0.0. Student’s unpaired/paired t test, one-way ANOVA 
with Bonferroni post hoc test, or repeated-measures ANOVA with 
LSD post hoc test was used as indicated. Data are shown as mean ± 
SEM, and the significance level was set to an  of 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/4/eaaw1567/DC1
Fig. S1. Docking poses of OZP and CPX.
Table S1. Hit list of the 3D- and 2D-based screens.
Table S2. Structures of all tested molecules (note that NQN, which has not been tested,  
is also shown).
Table S3. Ki values for CZP and OZP at different receptors and hM4D(Gi) EC50 (bold and 
indicated with an arrow).
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